Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer

23 Sept 2022

Abstract excerpt

High-grade serous ovarian cancer (HGSOC) is the deadliest ovarian cancer histotype due in-part to the lack of therapeutic options for chemotherapy-resistant disease. PARP inhibitors (PARPi) represent a targeted treatment. However, PARPi resistance is becoming a significant clinical challenge. There is an urgent need to overcome resistance mechanisms to extend disease-free intervals. We established isogeneic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Endoplasmic Reticulum Stress and Disease
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36149636
DOI: 10.1158/1541-7786.mcr-22-0102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian CancerPMID 36149636Read ↗

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repairSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

KLF4 promotes apoptosis evasion and PARP inhibitor resistance in BRCA2-mutated epithelial ovarian cancerSemantic proximity Read ↗

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO StudySemantic proximity Read ↗

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer CellsSemantic proximity Read ↗

Activation of Wnt signaling promotes olaparib resistant ovarian cancerSemantic proximity Read ↗

Targeting Wnt Signaling To Overcome PARP Inhibitor ResistanceSemantic proximity Read ↗

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read ↗

Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancerSemantic proximity Read ↗

Endoplasmic reticulum stress signaling actively contributes to therapy resistance in colorectal cancerSemantic proximity Read ↗

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.